• home
• about genphar
• management team
• scientific advisory board
• board of directors

about genphar...

board of directors

John Dong, M.D., Ph.D.

Dr. John Dong is President and Chief Scientific Officer of GenPhar, Inc. Under John's leadership, GenPhar, Inc. developed a unique vaccine platform upon which the company has created a number of multivalent vaccines against lethal viruses.  With a novel technology and promising research data, John established close collaborations with divisions of the United States Department of Defense (DoD) and National Institutes of Health (NIH). John's collaborations include: working with the Simian Vaccine Evaluation Unit of NIH to develop an HIV vaccine that induces both neutralizing and CTL responses; partnering with the US Army Research Institute of Infectious Diseases (USAMRIID) to develop a bivalent Ebola vaccine and a trivalent Marburg vaccine; and a joint effort with the US Navy Medical Research Center (NMRC) to challenge a tetravalent dengue vaccine against all four serotypes of the dengue virus.  John has also been leading the effort to develop the commercial applications of the platform, including a hepatitis C vaccine, hepatitis B vaccine and a West Nile virus vaccine. John currently serves as the principal investigator on a number of federally funded grants and contracts.

Dr. Dong also has a long academic career.  He obtained his medical degree at the Capital Medical Institute in Beijing, People’s Republic of China and his doctorate in molecular virology and immunology at the University of Alabama at Birmingham (UAB).  He joined the faculty at UAB almost immediately after obtaining his Ph.D. with joint affiliations with both the Department of Physiology and Biophysics and the Gregory Fleming James Cystic Fibrosis Research Center.  He then continued his successful academic career at the University of California-San Francisco (UCSF), and is currently a Professor in the Dept. of Microbiology and Immunology at the Medical University of South Carolina (MUSC). John is an expert in molecular virology and immunology and has published regularly in scientific journals such as the Journal of Virology, Human Gene Therapy, and the Proceedings of the National Academy of Sciences (PNAS).  John's research has resulted in multiple patent awards.

E-mail: dongj@genphar.com

Danher Wang, M.D., Ph.D.

Danher co-founded GenPhar in 1999 and serves as Vice President for Research and Development and Principal Scientist. She is one of the primary inventors of GenPhar’s universal vaccine platform and a developer of GenPhar’s candidate HIV vaccine. Dr. Wang oversees all research and development activities within the company and is a primary contact for our scientific and commercial collaborators. Danher received her M.D. from the Capital Medical Institute in Beijing, People’s Republic of China and was a micro surgeon in Beijing, China. She received her Ph.D. in the Cell and Molecular Biology Program of the Department of Microbiology at the University of Alabama at Birmingham (UAB). Her research career began at UAB when she worked in the Department of Cell Biology and later the Division of Nephrology.  She then continued her research career in the Dept. of Laboratory Medicine at the University of California, San Francisco.  She is an experienced molecular biologist and has published repeatedly in scientific journals such as Human Gene Therapy, American Journal of Physiology, and The Journal of Immunology.

E-mail: wangd@genphar.com

Yeung Heung Yeung

Mr. Yeung is the Chief Executive Officer of Tsinghua Yuanxing Pharmaceuticals, a major pharmaceutical company located in Shenzhen, China. Mr. Yeung has extensive experience managing pharmaceutical companies and has much knowledge of biopharmaceutical product development and investment administration. Yeung has been a board member of GenPhar since 2004. He graduated from the prestigious Tsinghua University in China, and his company, Tsinghua Yuanxing Pharmaceutical Co. (TY), maintains close ties to the University. TY has established a joint venture with GenPhar and will utilize Yeung’s knowledge of the industry to manufacture and market the company’s hepatitis B and AIDS vaccines to the greater China market.